Ozempic and similar weight-loss drugs were linked to a striking 30% reduction in breast cancer risk in a study of more than 110,000 women.
Popular weight-loss and diabetes medications such as Ozempic, Wegovy, Mounjaro, and Zepbound may offer an unexpected benefit beyond helping people lose weight. A large new study found that women taking these drugs were significantly less likely to develop breast cancer than women who were not using them.
The research, presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and published in JCO Oncology Practice, analyzed health records from more than 110,000 women. Researchers found that women taking GLP-1 medications, a class of drugs that includes semaglutide (the active ingredient in Ozempic and Wegovy) and similar treatments, had about a 30% lower risk of developing breast cancer.
"While our study was observational and does not definitively confirm an association between GLP-1 medications and reduced breast cancer incidence, it does add to the growing body of evidence suggesting that it's worth investigating these weight-loss drugs as potential cancer prevention tools," said Elizabeth McDonald, MD, PhD, a professor of Radiology at the University of Pennsylvania Perelman School of Medicine and a practicing breast radiologist at Penn's Abramson Cancer Center.
Ozempic and Similar Drugs Draw Interest From Cancer Researchers
GLP-1 medications mimic a naturally occurring hormone called glucagon-like peptide-1, which helps regulate blood sugar and appetite. Drugs in this category were originally developed for type 2 diabetes but have become household names because of their effectiveness for weight loss.
Ozempic and Wegovy contain semaglutide, while Mounjaro and Zepbound use a related medication called tirzepatide. Together, these drugs are now used by millions of Americans.
Researchers have increasingly become interested in whether these medications might also affect cancer risk. Several recent observational studies have linked GLP-1 drugs to lower rates of certain cancers or improved outcomes among cancer survivors. However, researchers stress that prospective clinical trials, considered the gold standard of medical research, are still needed.
McDonald and her colleagues are currently working to launch a multisite clinical trial to determine whether GLP-1 medications can help prevent breast cancer in women at elevated risk, including some with a history of the disease.
"GLP-1 medications are intriguing from a cancer research perspective because they weren't designed for cancer therapy, but they do affect many different targets and pathways associated with cancer development, so we're eager to study them in this context," McDonald said.
Study of More Than 110,000 Women Finds Lower Breast Cancer Rates
The researchers examined electronic health records from 111,646 women between the ages of 45 and 80 who had a body mass index (BMI) of 25 or higher and underwent breast imaging through Penn Medicine between January 2022 and June 2025.
Among these women, 15,264 (13.7 percent) had documented prescriptions for GLP-1 medications, while 96,382 (86.3 percent) had no documented exposure to the drugs.
The team looked for new breast cancer diagnoses in two groups. The first included the entire study population. The second included a smaller matched cohort of 30,528 women. In that analysis, each woman taking a GLP-1 drug was paired with a nonuser who shared similar characteristics, including age, race, ethnicity, BMI, breast density, and diabetes status.
The findings were consistent across both groups. In the full study population, GLP-1 users had 35.1 percent lower odds of developing breast cancer. In the matched analysis, the reduction was 30.5 percent.
The study did not account for the specific type of GLP-1 medication used, how long participants took the drugs, inherited genetic risk factors, or the stage and type of cancer diagnosed. Researchers plan additional analyses to explore some of these questions.
Why Might Ozempic and Other GLP-1 Drugs Affect Cancer Risk?
Maintaining a healthy weight has long been considered an important part of breast cancer prevention because excess body weight, especially after menopause, is a well-established risk factor.
Because Ozempic, Wegovy, Mounjaro, and Zepbound can produce substantial weight loss, some of the observed benefit may be linked to improved weight management. However, researchers believe other biological effects could also be involved.
Scientists have long suspected that chronic low-grade inflammation contributes to cancer development. GLP-1 medications reduce inflammation through multiple pathways and also influence metabolism and epigenetic processes that help regulate gene activity. Researchers currently believe this combination of effects may help slow or prevent tumor formation.
Searching for Better Ways to Prevent Breast Cancer
Current options for reducing breast cancer risk remain limited.
Beyond regular screening with mammography or MRI, some people with inherited genetic mutations that greatly increase breast cancer risk choose preventive surgery, including prophylactic mastectomy.
Tamoxifen can substantially reduce breast cancer incidence in high-risk women, but concerns about side effects have limited its use among many eligible patients.
Because GLP-1 medications such as Ozempic, Wegovy, Mounjaro, and Zepbound are already widely prescribed, researchers see them as a potentially promising avenue for future cancer prevention research.
"Ultimately, we want to find better options to prevent breast cancer," McDonald said. "It's been encouraging to see the survival rates for breast cancer improve over recent decades, and we'd love to see the same gains in prevention."
Reference: "GLP-1 Agonists Are Associated With a Significant Reduction in Breast Cancer Incidence in Women" by Elizabeth S. McDonald, Laura B. Gillis, Peter Gabriel, Kham Xapakdy, Anthony Young, Abigail Doucette, Mitchell D. Schnall, John B. Buse and Etta D. Pisano, 2 June 2026, JCO Oncology Practice.
DOI: 10.1200/OP-26-00485
The study was supported by the American College of Radiology Center for Research and Innovation, the Pennsylvania Breast Cancer Coalition, and the Abramson Cancer Center.
News – Curated by Amanda Scott, Alias Group Creative
Follow her on Bluesky
Micro-drones fly through the body thanks to ultrasound
At the EPFL, micro-drones have been developed that can be moved without a motor or battery.No motors, no batteries, no electronics on board, just small cavities that convert sound waves into thrust: this is [...]
A Single Enzyme Could Hold the Key to Treating a Devastating Brain Disorder
Blocking an enzyme’s production restored brain growth and healthy behaviors in mice engineered to develop Angelman syndrome, pointing to a possible treatment target. Children with Angelman syndrome begin to show difficulties with thinking and [...]
Scientists Develop a Clever New Way To Kill Cancer Cells From the Inside
Scientists have developed an experimental strategy that exploits a chemical byproduct of cancer cells to produce anticancer drugs directly inside them. Scientists in Japan have developed an experimental method that uses a chemical produced [...]
Our books are available worldwide!
Online Sellers other than Amazon, Routledge, and IOPP Indigo Global Health Care Equivalency in the Age of Nanotechnology, Nanomedicine and Artifcial Intelligence Global Health Care Equivalency In The Age Of Nanotechnology, Nanomedicine And Artificial [...]
After only a short training, people in a coma managed to send targeted signals
Researchers have succeeded in communicating with brain-injured patients who are unconscious. They see enormous potential in this for future treatments. Patients who lie motionless in bed after a severe brain injury and do not [...]
MIT Scientists Reprogram Immune Cells Inside the Body To Destroy Cancer
Natural killer cells reprogrammed inside mice eliminated lymphoma tumors and helped damaged livers heal, though whether this approach could help people with cancer or autoimmune disease remains unknown. To make a cancer treatment from [...]
Melanoma mRNA Vaccine Shows Promise in Preventing Disease Recurrence
Key takeaways: Phase 3 trial finds personalized intismeran plus pembrolizumab may better prevent high-risk melanoma recurrence after surgery The trial enrolled 1,137 patients and builds on phase 2 results showing about half the recurrence [...]
Scientists Discover a Powerful New Weapon Against a Dangerous Gut Infection
The promise of an experimental treatment for C. difficile gut infections lies partly in the bacteria it leaves alive, according to early laboratory and mouse research. Broad-spectrum antibiotics can disrupt the gut’s microbial community, [...]
Your Bones May Hold a Hidden Clue to Blood Cancer Survival
For people with blood cancers called myelodysplastic syndromes, osteoporosis may hold an overlooked clue to survival, a three-year observational study suggests. In blood cancers that develop in the bone marrow, an important clue to [...]
Researchers Discover What Reading for Pleasure May Be Doing to Your Brain
Reading for pleasure may offer surprising benefits for the brain, with research linking the habit to better mental health, stronger cognitive abilities, and a lower risk of dementia. Reading for pleasure may do far [...]
Scientists Discover a Hidden Trigger That Keeps Inflammation Alive
Inflammation persists after proteins detach from immune receptors, revealing a potential target for autoimmune treatments. Since a Nobel Prize-winning discovery in the 1990s identified molecules called Toll-like Receptors as the guardians of the human [...]
A Virus Gives Itself Away the Moment It Attacks
Researchers have found the trigger behind a powerful bacterial defense against viruses. Viruses that prey on bacteria could become an increasingly important tool for treating bacterial infections, particularly as antibiotic resistance makes some infections [...]
Scientists Discover Aspirin May Slash Dementia Risk by 70% – but Only for Certain People
Aspirin was linked to a sharply lower dementia risk in some older adults, and their genes may hold the clue. A Monash University analysis found that older adults with a particular genetic profile had [...]
Inflammation May Awaken Dormant Cancer Cells Years After Treatment
The body’s response to inflammation may disturb cancer cells that have been lying silent for years, giving them an opportunity to grow again. Researchers at the Francis Crick Institute have found that gut inflammation [...]
Where do nanoparticles go once they enter the body?
New international best practice guidance, co-written at ANSTO, sets out how to measure where nanoparticles like titanium dioxide end up in the body and how long they remain. The guidance has been shared by [...]
Long-Acting HIV Shots Could Solve a Major Treatment Challenge for Young People
A major African trial suggests that changing how HIV treatment is delivered could significantly improve viral suppression in adolescents. Young people with HIV were more likely to keep the virus suppressed when they received [...]
